We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.50 | GBX |
Salvarx (SALV) Share Charts1 Year Salvarx Chart |
|
1 Month Salvarx Chart |
Intraday Salvarx Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/3/2022 | 21:03 | SalvaRx Group - Jim Mellon/Oxford Uni Cancer Immunotherapy co (formerly 3LEG) | 547 |
| 25/6/2021 | 14:29 | SalvaRx Group - targeting tumours | 44 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 25/6/2021 14:29 by abadan2 I am a big holder of Portage via SALV. While I enjoyed seeing the Portage share price in the high $30s, I was aware that there had been no specific news that could necessarily support that price. A fund raising of $23m at $23 tells us that the serious investors who put up the money see meaningful upside from this level, which should be good news for the price once the dust settles. |
Posted at 25/6/2021 14:23 by abadan2 I am a big holder of Portage via SALV. While I enjoyed seeing the POit was |
Posted at 20/2/2021 13:19 by the stigologist $100 translates to a Mkt Cap of c.$1bn which is below the average value of US quoted Clinical Stage Biotechs apparentlyPortage is better than your average biotech IMO so I expect the Company to list at around $100 and go up from there. Apparently someone has been in email contact with Jim Mellon re SALV and there are things going on. Much more promising talk that I'd have expected given SALV would be such a small part of Mellon's empire. Clearly has plans for it. |
Posted at 31/1/2021 00:13 by bscuit There were 60.8M Portage shares now consolidated at 608,000 valued @$US23 plus any cash value from warrants held by SALV, though I don’t know number of shares in issue. Curiously I cannot find SALV on CH Webcheck to check shares in issue. Company maintenance costs will have had to be paid - presumably from share sales. The Listing has now no value in my opinion as it was an AiM company. |
Posted at 31/12/2020 17:13 by cumbrian2 Unless SALV have disposed of their Portage shares, I believe they still own 566,575 shares which would equate to $9.77 million @ 17.25 mid price currently. This would equate to 19.5p per old SALV share. I still own 334,762 of the old SALV shares so am hoping for dome news from them in the not too distant future! Just hoping they haven't sold many of their Portage shares in order to ''cover expenses'' and shafted the shareholders - heres hoping! Still hold 10,000 PTGEF shares from SALV days, so currently very happy, hoping foe news to make me ''ecstatic''!!!! |
Posted at 16/11/2020 09:33 by the stigologist Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) (“Portage̶The Loan Notes were originally issued in 2017. At that time, SalvaRx was a subsidiary of SalvaRx Group plc, a publicly listed company on the AIM board of the London Stock Exchange. Under the terms of the Loan Notes, upon the occurrence of a qualifying event, Loan Note holders would have been entitled to receive share purchase warrants of SalvaRx in addition to repayment of their Loan Note. The acquisition of SalvaRx by the Company in 2019 constituted a qualifying event. The Company has settled the Loan Note obligations of SalvaRx through the issuance of the Settlement Securities. Four of the Company’s directors, Gregory Bailey, James Mellon, Steven Mintz (in trust) and Kam Shah have received an aggregate of 363,718 common shares as they had all originally subscribed for Loan Notes in 2017 in an aggregate principal amount of approximately US$4.0 million. The issuance of the common shares to these directors is considered a related party transaction within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on appropriate exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 in respect of these issuances. Dr. Ian Walters, CEO of Portage, commented, “As a result of this transaction, the Company’s capital structure is simpler and effectively debt free, providing significant financial flexibility to further fund and expand development of innovative drugs to help cancer patients.” All Common Shares issued in connection with the Offering are subject to a minimum statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Common Shares issued in connection with the Offering have not been registered under the U.S. Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available. |
Posted at 03/5/2019 19:41 by bscuit Anyone else got a similar problem?Originally I retained my rump SALV shares and in retrospect should have sold at 20p, but sold prior to the end of the tax year at 9p. Because they were subscribed shares. I could in theory set any loss against Income Tax using Subscribed Share Income Tax Loss Relief, but I have retained myPortage shares. In the context of completion of my tax return, my accountant advises that he requires the split in value of my original holding between SALV and Portage immediately following the de-merger. I contacted share price Angel – successors to Northland, who advised that immediately following approval of the De-merger, the SALV price was 75.5p and that Portage was trading atCAN$0.115, meaning that each SALV share pre-demerger was worth CAN$2.07 plus the rump value. The information from share price Angel is in my view flawed as the 75.5p included the about to be de-merged value in Portage. There should be a de-merger value on both shares. I that my accountant will not accept that the value of my SALV shares is showing a significant loss on original subscription price when I have an asset which I have retained. Any thoughts? In my opinion that has been a failure by SALV and its advisers to inform shareholders of the split in value in a fractional as opposed to pounds and p pennies in order for the calculation of the loss on the original holding – if any – or any fractional gain. |
Posted at 06/3/2019 20:42 by dexdringle Given that the rump of the Portage shares are the only SALV asset now, should we not be expecting ths SALV share price to move broadly in line with the Portage share price ? |
Posted at 09/1/2019 08:08 by dexdringle Okay. Just to re-cap. SALV will become the owner of 757M Portage shares in exchange for signing over its trading business to Portage. SALV then becomes an investment businessSALV then plans to simply pass on 90% the Portage shares to its own shareholders so we will end up each owning X number of shares in Portage (plus our existing SALV shares albeit probably around 10p a share at that point reflecting the value of the Portage shares not distributed). Questions: 1. how long is it likely to be before the distribution takes place ? 2. how simple is it for a UK shareholder to directly own (and trade) shares in Portage ? Presumably, the SALV share price will, from today, exactly reflect the value of the Portage shares and could be sold before the distribution happens ? EDIT: just noticed the SALV share price has dropped to 10p so already prices in the distribution ? |
Posted at 08/12/2018 14:24 by cumbrian2 Agreed Stig, but probably best to use the latest offer price which was $0.105 but that still gives a GBP1.49 conversion. My concern was that Portage would open very weakly yesterday which was not the case, so assuming they hold the current level then the arbitrage has to kick in big time as we head to completion date. Adding in, that we retain the SALV shell(which may get a Juvinescence investment?), and that the said shell retains some Portage shares then the SALV share price looks ''too good to be true'' but looks like it actually is!!! Thankfully own 144k shares, all bought after the original deal (based on my view on Intensity) so averaging 67p but hopeful of a big profit to come! Got to be heading higher on Monday. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
